{Reference Type}: Journal Article
{Title}: Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.
{Author}: Murzyn A;Orzeł J;Obajtek N;Mróz A;Miodowska D;Bojdo P;Gąsiorkiewicz B;Koczurkiewicz-Adamczyk P;Piska K;Pękala E;
{Journal}: Cancer Chemother Pharmacol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 4
{Factor}: 3.288
{DOI}: 10.1007/s00280-024-04693-1
{Abstract}: Aclarubicin (aclacinomycin A) is one of the anthracycline antineoplastic antibiotics with a multifaceted mechanism of antitumor activity. As a second-generation drug, it offers several advantages compared to standard anthracycline drugs such as doxorubicin or daunorubicin, which could position it as a potential blockbuster drug in antitumor therapy. Key mechanisms of action for aclarubicin include the inhibition of both types of topoisomerases, suppression of tumor invasion processes, generation of reactive oxygen species, inhibition of chymotrypsin-like activity, influence on cisplatin degradation, and inhibition of angiogenesis. Therefore, aclarubicin appears to be an ideal candidate for antitumor therapy. However, despite initial interest in its clinical applications, only a limited number of high-quality trials have been conducted thus far. Aclarubicin has primarily been evaluated as an induction therapy in acute myeloid and lymphoblastic leukemia. Studies have indicated that aclarubicin may hold significant promise for combination therapies with other anticancer drugs, although further research is needed to confirm its potential. This paper provides an in-depth exploration of aclarubicin's diverse mechanisms of action, its pharmacokinetics, potential toxicity, and the clinical trials in which it has been investigated.